The smart drug delivery conundrum

One of the concerns these days about self-assembling nanotechnology is that it is so advanced beyond the current drug paradigm that it becomes problematic from a regulatory point of view. Let’s say, for example, that you have a patient admitted to an oncology ward.  The doctor decides to get a biopsy to assess the nature … Read more…